The Choice of Insulin Type and Regimen for Adolescents with Type 1 Diabetes during Ramadan Fasting: A Continuing Debate

Reem Hassan-Beck; Asma Deeb

doi:10.1055/s-0042-1756469

Journal of Diabetes and Endocrine Practice, Table of Contents

CC BY-NC-ND 4.0 · Journal of Diabetes and Endocrine Practice 2022; 05(02): 047-049
DOI: 10.1055/s-0042-1756469

Commentary

The Choice of Insulin Type and Regimen for Adolescents with Type 1 Diabetes during Ramadan Fasting: A Continuing Debate

Authors

Reem Hassan-Beck

¹Clinical Trial Unit, Sheikh Shakhbout Medical City, Abu Dhabi, United Arab Emirates

²Division of Pediatric Endocrinology, Sheikh Shakhbout Medical City, Abu Dhabi, United Arab Emirates
Asma Deeb

²Division of Pediatric Endocrinology, Sheikh Shakhbout Medical City, Abu Dhabi, United Arab Emirates

³College of Medicine and Health Science, Khalifa University, Abu Dhabi, United Arab Emirates

Abstract

Full Text

References

References
1 Hassanein M, Afandi B, Yakoob Ahmedani M. et al. Diabetes and Ramadan: practical guidelines 2021. Diabetes Res Clin Pract 2022; 185: 109185
2 Kaplan W, Afandi B, Al Hassani N. Comparison between insulin glargine and insulin detemir in adolescents with type 1 diabetes during Ramadan fasting. J Diabetes Endocrine Pract 2022; 5 (02) 61-64
3 Beshyah SA, Habeb AM, Deeb A, Elbarbary NS. Ramadan fasting and diabetes in adolescents and children: a narrative review. Ibnosina J Med Biomed Sci 2019; 11 (02) 47-56
4 Hayakawa T, Ishii M, Watanabe M. et al. Replacement of neutral protamine Hagedorn insulin with the long-acting insulin analogue, detemir, improves glycemic control without weight gain in basal-bolus insulin therapy in Japanese patients with type 1 diabetes. J Diabetes Investig 2011; 2 (01) 71-77
5 Cunningham AM, Freeman AM. Glargine Insulin. StatPearls [Internet]. Treasure Island, FL: StatPearls Publishing; 2022
6 Scheen A, Radermecker R, Philips J, Paquot N. 2022 . [Insulin detemir (Levemir)]. [online] PubMed. Accessed July 27, 2022 at: https://pubmed.ncbi.nlm.nih.gov/16358671/
7 Al-Arouj M, Assaad-Khalil S, Buse J. et al. Recommendations for management of diabetes during Ramadan: update 2010. Diabetes Care 2010; 33 (08) 1895-1902
8 Karamat MA, Syed A, Hanif W. Review of diabetes management and guidelines during Ramadan. J R Soc Med 2010; 103 (04) 139-147
9 Ibrahim M, Abu Al Magd M, Annabi FA. et al. Recommendations for management of diabetes during Ramadan: update 2015. BMJ Open Diabetes Res Care 2015; 3 (01) e000108
10 Ahmed MH, Abdu TA. Diabetes and Ramadan: an update on use of glycemic therapies during fasting. Ann Saudi Med 2011; 31 (04) 402-406
11 Lessan N, Hannoun Z, Hasan H, Barakat MT. Glucose excursions and glycaemic control during Ramadan fasting in diabetic patients: insights from continuous glucose monitoring (CGM). Diabetes Metab 2015; 41 (01) 28-36
12 Frier BM, Ratzki-Leewing A, Harris SB. Reporting of hypoglycaemia in clinical trials of basal insulins: a need for consensus. Diabetes Obes Metab 2019; 21 (07) 1529-1542
13 Al-Khawari M, Al-Ruwayeh A, Al-Doub K, Allgrove J. Adolescents on basal-bolus insulin can fast during Ramadan. Pediatr Diabetes 2010; 11 (02) 96-100
14 Cameron FJ, Garvey K, Hood KK, Acerini CL, Codner E. ISPAD Clinical practice consensus guidelines 2018: diabetes in adolescence. Pediatr Diabetes 2018; 19 (Suppl. 27) 250-261
15 Oya J, Nakagami T, Hasegawa Y, Katamine A, Kondo Y, Babazono T. Comparative clinical outcomes of insulin degludec and insulin glargine 300 U/mL after switching from other basal insulins in real-world patients with type 1 and type 2 diabetes. J Diabetes Investig 2021; 12 (11) 1983-1991
16 Kalra S. Insulin degludec and insulin degludec/insulin aspart in Ramadan: a single center experience. Indian J Endocrinol Metab 2016; 20 (04) 564-567
17 Hassanein M, Buyukbese MA, Malek R. et al. Real-world safety and effectiveness of insulin glargine 300 U/mL in participants with type 2 diabetes who fast during Ramadan: the observational ORION study. Diabetes Res Clin Pract 2020; 166: 108189